Among 37 patients with cancers other than gastric, GEJ, or esophageal cancers in whom HER2-targeted treatment was given in the second line or later and for whom previous treatment information was available, the PFS2-to-PFS1 ratio was 1.3 or greater in 21 patients (57%), and the median PFS2 and PFS1 times were 24 and 13 weeks, respectively (P < .001; Fig 4). The gene discussed is ERBB2; the disease is esophageal cancer.